10-Q: HeartBeam Inc. Reports Q1 2025 Results, Highlights FDA Progress and Strategic Collaborations

HeartBeam, Inc. announces its Q1 2025 financial results, showcasing progress in FDA clearances and strategic partnerships aimed at enhancing its cardiac monitoring solutions.

Summary

• HeartBeam, Inc. reported a net loss of $5.484 million, or $0.18 per share, for the three months ended March 31, 2025, compared to a net loss of $4.606 million, or $0.17 per share, for the same period in 2024.
• The company's general and administrative expenses decreased by 15% to $2.012 million, while research and development expenses increased by 44% to $3.492 million.
• HeartBeam completed a public offering in February 2025, raising $11.5 million in gross proceeds and strengthening its balance sheet with $8.2 million in cash and short-term investments as of March 31, 2025.
• The company received FDA clearance for its HeartBeam System in December 2024 and filed a 510(k) application for its 12L ECG synthesis software in January 2025.
• A pivotal study, VALID-ECG, demonstrated a 93.4% overall diagnostic agreement between HeartBeam's synthesized 12-lead ECG and standard 12L ECGs for arrhythmia assessment.
• HeartBeam initiated an early access program for the HeartBeam System and announced a strategic collaboration with AccurKardia to integrate their automated ECG interpretation platform.
• The company has 20 issued patents worldwide and is actively pursuing AI development efforts with a database of approximately one million standard 12L ECGs.

Sentiment

Score: 5

Explanation: The company is making progress on its FDA clearances and strategic collaborations, but it is still incurring losses and has substantial doubt about its ability to continue as a going concern. The recent capital raise is a positive, but the company will need to continue to raise capital to fund its operations.

Positives

• HeartBeam successfully completed a public offering, bolstering its cash position.
• The company achieved FDA clearance for its HeartBeam System.
• The VALID-ECG pivotal study demonstrated strong diagnostic agreement for the company's 12L ECG synthesis software.
• HeartBeam is actively pursuing strategic collaborations to enhance its product offerings.
• The company is expanding its intellectual property portfolio with new patents.
• The company is actively developing AI capabilities to enhance its products.

Negatives

• HeartBeam continues to incur net losses and negative cash flows from operations.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company expects no material commercial revenue in 2025.
• The company's existing liquidity is insufficient to fund operations for the next twelve months.

Risks

• HeartBeam's ability to continue as a going concern is dependent on raising additional capital.
• The company's success is dependent on receiving FDA clearance for its 12L ECG synthesis software.
• The company faces competition from larger companies and other technologies.
• The company's commercial success is dependent on market acceptance of its products.
• The company is subject to risks associated with early-stage companies, including dependence on key individuals.

Future Outlook

HeartBeam anticipates a commercial launch of its products once it receives FDA clearance for its 12L synthesis software and expects to continue its AI development efforts and strategic collaborations.

Management Comments

• Management believes the continued achievement of critical clinical and regulatory milestones will provide the Company the ability to raise additional capital.
• Management performed its probability assessment regarding the milestone achievement date and concluded that based on current status of discussion with FDA and planned V2 submission, no change in the estimated clearance date of December 31, 2025.

Industry Context

HeartBeam is operating in the rapidly growing field of ambulatory cardiac health monitoring, addressing the need for accessible and high-fidelity ECG solutions outside of traditional healthcare settings.

Comparison to Industry Standards

• The company is developing technology to compete with existing ambulatory ECG monitoring solutions, such as those offered by iRhythm Technologies, Inc. and BioTelemetry, Inc.
• The company's goal is to provide diagnostic capabilities comparable to traditional hospital-based ECG systems, but in a more convenient and accessible format.
• The company's collaboration with AccurKardia is intended to enhance its product offering by adding automated ECG interpretation capabilities, similar to those offered by other companies in the cardiac monitoring space.

Corporate Governance

Related Party Transactions

• During April 2024, the Company entered into consulting agreement with one of the independent Board of Directors to provide business development consulting services.

Stakeholder Impact

• Shareholders: The company's financial performance and ability to raise capital will impact shareholder value.
• Employees: The company's ability to fund its operations will impact employee job security.
• Customers: The company's ability to obtain FDA clearance and commercialize its products will impact the availability of its cardiac monitoring solutions.
• Suppliers: The company's ability to pay its obligations will impact its relationships with suppliers.
• Creditors: The company's ability to repay its debts will impact its relationships with creditors.

Next Steps

• The company will continue to pursue FDA clearance for its 12L ECG synthesis software.
• The company will continue to develop its AI capabilities.
• The company will continue to pursue strategic collaborations.
• The company will hold its annual meeting in July 2025.

Key Dates

Keywords

HeartBeam, ECG, cardiac monitoring, FDA clearance, arrhythmia, telehealth, clinical study, financial results, patents, AI